<DOC>
	<DOCNO>NCT01557400</DOCNO>
	<brief_summary>Duchenne/Becker muscular dystrophy ( DBMD ) genetic disorder develop boy . It cause mutation gene dystrophin , protein important maintain normal muscle structure function . Loss dystrophin cause muscle fragility lead weakness loss walk ability childhood teenage year . A specific type mutation , call nonsense ( premature stop codon ) mutation , cause DBMD approximately 10-15 % boys disease . Ataluren orally deliver , investigational drug potential overcome effect nonsense mutation . This study open-label trial patient nonsense mutation dystrophinopathy receive ataluren prior PTC-sponsored study clinical trial site Europe , Israel , Australia , Canada . The primary objective study evaluate long-term safety ataluren , determine adverse event laboratory abnormality .</brief_summary>
	<brief_title>Study Ataluren Previously Treated Patients With nmDBMD Europe , Israel , Australia , Canada</brief_title>
	<detailed_description>The study enroll boys nonsense mutation DBMD history exposure ataluren prior PTC study nmDBMD ( PTC124-GD-004-DMD , PTC124-GD-004e-DMD , PTC124-GD-007-DMD , PTC124-GD-007e , PTC124-GD-008-DMD ) trial site Europe , Israel , Australia , Canada . Patients receive study drug 3 time per day ( breakfast , lunch , dinner ) . Study assessment perform clinic visit screen every 12 week 96-week treatment period . Patients must also return clinic post-treatment visit 6 week last dose ataluren .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Evidence sign date informed consent/assent document ( ) indicate subject ( and/or parent/legal guardian ) inform pertinent aspect trial History exposure ataluren prior PTC study nmDBMD Male sex Confirmed screen laboratory value within specify range In subject sexually active , willingness abstain sexual intercourse employ barrier medical method contraception ataluren administration 6week follow period Willingness ability comply schedule visit , drug administration plan , study procedure , laboratory test , study restriction Exposure another investigational drug within 1 month prior start study treatment Eligibility another ataluren clinical trial actively enrol study participant Known hypersensitivity ingredient excipients study drug Ongoing use follow medication : coumarin base anticoagulant , phenytoin , tolbutamide , paclitaxel , systemic aminoglycoside therapy Ongoing uncontrolled medical/surgical condition , ECG finding , laboratory abnormality , investigator 's opinion , could adversely affect safety patient make unlikely followup would complete</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>Becker muscular dystrophy</keyword>
	<keyword>Nonsense mutation</keyword>
	<keyword>Premature stop codon</keyword>
	<keyword>DMD</keyword>
	<keyword>BMD</keyword>
	<keyword>nmDBMD</keyword>
	<keyword>DBMD</keyword>
	<keyword>Ataluren</keyword>
	<keyword>PTC124</keyword>
</DOC>